Ayisha Jeter Joins Arcutis as Vice President of Market Access
June 01 2020 - 9:00AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Ayisha Jeter has joined the company as Vice President of
Market Access. In this new role, Ms. Jeter will be
responsible for Arcutis’ access and reimbursement efforts as the
Company prepares for the potential future commercialization of its
product candidates.
“Ayisha is a dynamic market access executive
with 18 years of biopharmaceutical and pharmaceutical industry
experience, encompassing sales, managed markets and access
marketing, distribution and trade, patient services, and product
launches,” said Ken Lock, Arcutis’ Chief Commercial Officer.
“Ayisha’s expertise in developing market access and pricing
strategies in extremely competitive markets will be especially
invaluable as we continue our evolution toward becoming a
fully-integrated, commercial-stage dermatology company.”
Prior to joining Arcutis, Ms. Jeter held
multiple access leadership roles, culminating in the position of
Vice President of Managed Markets and Access Marketing, at Assertio
(formerly Depomed, Inc.) from 2015 to 2020. Before that, Ms.
Jeter was Associate Director, Payer Market (Portfolio Strategy), at
Purdue Pharma from 2013 to 2015. Previously, Ms. Jeter held the
position of Senior Analyst, Market Access Marketing, at Vivus, Inc.
from 2012-2013. Prior to that Ms. Jeter held a variety of sales
roles at Novartis Vaccines and Diagnostics; Genzyme, Inc.; and
Pfizer, Inc. Ms. Jeter received her B.A. in American Studies from
the University of California at Berkeley and her M.B.A. from the
Fuqua School of Business at Duke University.
About Arcutis - Bioscience, applied to the
skin.Arcutis is a late-stage biopharmaceutical company focused on
developing and commercializing treatments for unmet needs in
immune-mediated dermatological diseases and conditions, or
immuno-dermatology. Arcutis exploits recent innovations in
inflammation and immunology to develop potential best-in-class
therapies against validated biological targets, leveraging our deep
development, formulation and commercialization expertise to bring
to market novel dermatology treatments, while maximizing our
probability of technical success and financial resources.
Arcutis is currently developing four novel compounds, including
ARQ-151 (topical roflumilast cream); ARQ-154 (topical roflumilast
foam); ARQ-252, and ARQ-255 for multiple indications, including
psoriasis, atopic dermatitis, seborrheic dermatitis, and eczema,
vitiligo, and alopecia areata. For more information, please visit
www.arcutis.com or follow the Company on LinkedIn.
Forward Looking StatementsThis
press release contains forward-looking statements, including but
not limited to statements regarding Arcutis’ potential to become a
fully-integrated, commercial-stage dermatology company. Such
forward-looking statements involve substantial risks and
uncertainties that could cause Arcutis’ clinical development
programs, future results, performance or achievements to differ
significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in the drug development
process, including the clinical trial enrollment process,
regulatory approval processes, the potential timing of regulatory
filings, the challenges associated with manufacturing drug
products, Arcutis’ ability to successfully protect and defend its
intellectual property, and other matters that could affect the
sufficiency of existing cash to fund operations and the
availability or commercial potential of Arcutis product candidates.
Arcutis undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties applicable to our business, see the "Risk
Factors" section of our Form 10-Q filed with U.S. Securities and
Exchange Commission (SEC) on May 12, 2020, as well as any
subsequent filings with the SEC. We undertake no obligation to
revise or update information herein to reflect events or
circumstances in the future, even if new information becomes
available.
Investors and Media:Heather Rowe ArmstrongVice
President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024